Table 2.

Effect of tolvaptan 15, 30 and 45 mg at baseline, during and after NO-inhibition on pulse wave velocity (PWV), augmentation index (AI), central diastolic and systolic blood pressure (CBDP and CSBP) in a randomized, placebo-controlled, double-blind, crossover, dose-response study of 15 healthy subjects

	Prior to L-NMMA infusion (at 70 min)	During L-NMMA infusion (at 130 min)
PWV(m/s)
Placebo	5.2 ± 0.5	5.4 ± 0.5
Tolvaptan 15 mg	5.0 ± 0.5	5.4 ± 0.6**
Tolvaptan 30 mg	5.2 ± 0.6	5.5 ± 0.6 **
Tolvaptan 45 mg	5.2 ± 0.3	5.5 ± 0.4**
p (ANOVA)	0.518	0.851
AI
Placebo	−0.7 ± 13.8	0.1 ± 15.1
Tolvaptan 15 mg	−1.5 ± 12.5	−1.2 ± 17.3
Tolvaptan 30 mg	−0.4 ± 11.8	2.5 ± 17.8
Tolvaptan 45 mg	−3.3 ± 15.8	1.6 ± 12.0*
p (ANOVA)	0.968	0.961
CSBP
Placebo	97 ± 9	100 ± 8**
Tolvaptan 15 mg	97 ± 9	101 ± 10*
Tolvaptan 30 mg	96 ± 9	102 ± 9**
Tolvaptan 45 mg	96 ± 8	102 ± 6**
p (ANOVA)	0.989	0.952
CDBP
Placebo	63 ± 7	68 ± 6***
Tolvaptan 15 mg	63 ± 7	68 ± 9**
Tolvaptan 30 mg	61 ± 6	68 ± 7***
Tolvaptan 45 mg	62 ± 5	68 ± 6**
p (ANOVA)	0.936	0.998

Data are presented as mean ± SD. One-way ANOVA was performed to test differences between treatments groups. Paired t-test (*) was used for comparison of data during L-NMMA infusion vs prior to L-NMMA infusion

*p < 0.05; **p < 0.001; ***p < 0.0001